(TX_PVLS) Percentage of ART patients with a suppressed viral load (VL) result (<1000 copies/ml) documented in the medical or laboratory records/laboratory information systems (LIS) within the past 12 months
Number of ART patients with suppressed VL results (<1,000 copies/ml) documented in the medical or laboratory records/LIS within the past 12 months
Number of ART patients with a VL result documented in the medical or laboratory records/LIS within the past 12 months.
How to calculate annual total:
This indicator should be collected from clinical sources (e.g., electronic or paper patient records), where possible, to ensure de-duplicated patient counting and receipt of results to inform patient care. Ideally, data for this indicator should be collected from an electronic medical records system (EMR) to minimize data collection errors and ensure that results are informing patient care. If data collection from an EMR is not possible, indicator data may be collected from paper-based registers or reports that reflect the VL results. If standard patient registers do not contain all the required information, individual patient records should be reviewed.
If a clinical source does not exist or does not contain the desired information, data may be extracted from an electronic laboratory information system (LIS). VL results from an LIS must be linked to back to the individual patients and their record at sites.
NOTE: If patient-linked VL results from LIS is used for reporting, it is incumbent that the implementing partner ensure this information is transcribed into the patient record for timely VL results utilization/patient management.
The data source used for reporting on this indicator should be specified and data reported should be de-duplicated and used to inform patient care at sites. If the LIS is used, please explain why clinical sources could not be used to report on this indicator in the narrative (see guiding narrative question section below).
VL results should be reported for patients who have been on ART for at least 3 months (or according to national guidelines). It is important to ensure that the data sources used to collect and aggregate data are updated to be able to report VL results data for patients who have been on ART for at least 3 months.
The indicator reporting frequency is now quarterly. The reporting period still covers a 12-month period and may include data from the previous fiscal year (see visual below). For example, when reporting data in FY19 Q1, country teams will be required to report data for FY18 Q2+ FY18 Q3+FY18 Q4+ FY19 Q1.
Both only VL tests with recorded results and VL results that are linked back to patients should be included in the numerator and denominator of this indicator.
This indicator should be reported for all PEPFAR-supported treatment sites (i.e., from all reporting TX_CURR). VL monitoring result utilization should be promoted for individual patient, site, and program use. If a PEPFAR-supported treatment site (i.e., a site that has reported TX_CURR) has not collected any samples for VL testing, “0” should be entered for both the numerator and denominator.
Where more than one result is available for the reporting period, the most recent result should be reported. Programs should describe the method(s) of data collection and the results de-duplication methodology utilized in their narratives.
How to review for data quality:
Disaggregate descriptions & definitions:
Indication Disaggregate Definitions:
Only patients who have been on ART for at least 3 months should be considered.
Indicator changes (MER 2.0 v2.2 to v2.3):
PEPFAR Support definition:
Standard definition of DSD and TA-SDI used.
Provision of key staff or commodities for PLHIV on ART who receive VL monitoring includes: the provision of key staff and/or commodities can include ongoing procurement of critical commodities, such as ARVs, or funding for salaries of HCW who deliver VL monitoring services. Staff who are responsible for the completeness and quality of routine patient records (paper or electronic) can be counted here; however, staff who exclusively fulfill MOH and donor reporting requirements cannot be counted.
Ongoing support for PLHIV receiving ART VL monitoring improvement includes: clinical mentoring and supportive supervision of staff at HIV sites providing ART and VL monitoring services, support for quality improvement activities, patient tracking, enhanced adherence counseling system support, routine support of VL related M&E and reporting, VL related commodities consumption forecasting and supply management
Guiding narrative questions: